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Abstract 
Cancer is a world-wide problem. One third of cancer cases are breast cancer. Most of the breast 
cancer cases are in postmenopausal women due to increased estrogen production. Postmenopausal 
women have an increased risk of developing breast cancer because the estrogen production takes 
place in the adipose tissue. Furthermore postmenopausal with increased BMI are at greater risk of 
developing breast cancer due to increased estrogen production in the adipose tissue. Statins are used 
as treatment of hypercholesterolemia, which more often occurs in postmenopausal women. It is 
suggested that statins have other effects than preventing hypercholesterolemia. One of these effects 
is an anticancer effect. This is suggested due to statins influence on different pathways and interme-
diates. In this report, the purpose was to investigate whether it could be estimated if statin use re-
duces the recurrence risk of breast cancer. Through analyzing different meta-analyses and studies it 
could be estimated that statins did have a positive effect on breast cancer recurrence but further re-
search should be made. 
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Preface 
This report is written by a 4
th
 semester group on the subject module of Medicinal Biology at Ros-
kilde University in the spring semester 2015. 
We would like to thank our supervisor, Peter Michael Vestlev, for his supervision. 
Target group 
The target group of the following report is 4
th
 semester students studying medicinal- and molecular 
biology with basic education on and knowledge of human physiology and cell biology. The project 
could also be of interest for those who have knowledge of and interest in the topic. 
Project scope 
The focus in the project report will be on postmenopausal women with estrogen-receptor positive 
(ER +) breast cancer treated with a third generation nonsteroidal aromatase inhibitor, preferably 
letrozole. 
The meta-analyses and studies processed in this report do not necessarily encompass all these crite-
ria but at least one of them. 
The specific statistics and methods utilized in the processed meta-analyses and studies are not ac-
counted for in this report due to none of us have had a statistics course yet. 
Method  
To answer the problem of interest the report examined literature studies and data extraction from 
patients’ medical history and wished to use recent information based on criteria from studies, books, 
reviews, meta-analyses and results from studies. The report selected two articles from the meta-
analysis based on the criteria to examine the results in the articles compared to the meta-analyses. 
Introduction 
Cancer is a world-wide disease with estimated 1,658,370 new cases in 2015 (American Cancer So-
ciety.com). Up to one third of these cases are breast cancers (Russo et al., 2000). In Denmark 
37,000 new cases of cancers were registered in 2013 (Cancerregistret.dk). In regard to breast cancer 
in women in Denmark, approximately 4,700 new cases were registered in 2013 (Cancerregis-
tret.dk). The risk of breast cancer increases in proportion to increasing age. Thus postmenopausal 
women have a higher risk of developing breast cancer. Furthermore, breast cancer and breast cancer 
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risk are to a great extent associated with estrogen which initiates and promotes breast cancer devel-
opment (Yager & Davidson, 2006). The primary production of estrogen in postmenopausal women 
is not in the ovaries in premenopausal women, but in the peripheral tissue, especially the adipose 
tissue. Thus postmenopausal women with a high BMI are particularly at risk of developing breast 
cancer. Increased BMI also needs to be taken into consideration in regard to recurrence risk. 90 % 
of all women with breast cancer in Denmark are at risk of recurrence (cancer.dk). In Denmark 
postmenopausal women with  (HER+) breast cancer receives an anti-hormonal treatment called 
aromatase inhibitors, typically letrozole (cancer.dk). Treatment with letrozole has been shown to 
lead to a five-year disease-free survival of 84 % (BIG1-98 Collaborative Group). 
Furthermore approximately 30 % of postmenopausal women in Denmark are prescribed statins to 
treat hypercholesterolemia (SSI.dk) resulting from elevated cholesterol levels (Lehninger, 2013). 
Statins function by inhibiting HMG-CoA reductase and thus preventing the synthesis of cholesterol 
(Ahern et al., 2014). Besides statins’ use as treatment of hypercholesterolemia, statins have some 
pleiotropic effects including anticancer effects (Ahern et al., 2014) and in some cases they have 
been shown to reduce the recurrence risk of breast cancer among Danish women (Ahern et al., 
2011a). 
Statins are very inexpensive and tolerable, and thus they would be ideal in the treatment of breast 
cancer patients (Ahern et al., 2014) if they are shown to have a considerable positive effect, but this 
needs to be further investigated. The aim of this report was to estimate such an association based on 
the findings in epidemiological studies. 
Problem of interest 
With basis in epidemiologic studies, is it possible to estimate whether statins reduce the risk of re-
currence of ER+ breast cancer in postmenopausal women receiving letrozole treatment, or not? 
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Theory 
1.1 Breast cancer 
Breast cancer is the uncontrolled growth of abnormal cells in the breast tissue and the most common 
cancer type among women(James et al., 2015). It has been estimated that 1,200,000  new cases oc-
cur every year worldwide (Lumachi et al., 2013) and represents 11 %  among all cancer types glob-
ally (Majeed et al., 2014). Breast cancer is more common in postmenopausal women (Smith & 
Dowsett, 2003) and one third of all new cases of women’s cancer in North (Russo, Hu, Yang, & 
Russo, 2000). The breast cancer mortality is declining in certain industrialized countries but the 
opposite is observed in nations with lower breast cancer incidence (Russo et al., 2000). In the last 5 
decades the death from breast cancer has remained almost the same, due to the lack of knowledge 
about cancer progression and initiation (Russo et al., 2000). There are several factors causing the 
occurrence of breast cancer such as smoking, drinking alcohol, hormone therapies, physical inactiv-
ity, postmenopausal obesity, early menarche, delayed first childbirth and family history of cancer in 
breast, endometrium and ovary (Russo et al., 2000). The major cause is inherited mutations in the 
genes BRCA1 and BRCA2.  Gene mutation contribute to approximately 10-15 % of all cases 
(Majeed et al., 2014). After normal cells have completed their life cycle, they undergo apoptosis. 
Before initiation of apoptosis, several pathways (PI3K/AKT and RAS/MEK/ERK) and proteins 
(PTEN proteins) protect the cells. Mutation in genes that are associated with those pathways result 
in continuous cell division and proliferation and prevent apoptosis (Majeed et al., 2014). PTEN pro-
teins turn off the PI3K/AKT pathway, so a mutation in these proteins causes uncontrolled prolifera-
tion of tumor cells (Majeed et al., 2014). 
1.2 Breast cancer subtypes 
There are several types of breast cancers. Among these, 70 % is hormone-dependent (HD) 
(Lumachi et al., 2013) meaning that these cancer cells and tumors have hormone receptors (HR). 
There are two kinds of these receptors in the nucleus, the estrogen receptor (ER) and progesterone 
receptors (PR) (Lumachi et al., 2013). ER is the primary transcription factor driving oncogenesis in 
HR+ breast cancer (Lumachi et al., 2013). There are two kinds of ER in the ER tumor cells, those 
that found in the cell membrane and those in the cell nuclei (Edwards & Boonyaratanakornkit, 
2003). HD breast cancers depend on the presence of estrogen and/or progesterone for cell growth 
and proliferation (Lumachi et al., 2013). Another receptor is the human epidermal growth factor 
receptor 2 (HER2), a protein (Lumachi et al., 2013) that is located on the cell surface. The activa-
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tion of HER2 leads to activation of downstream pathways that promotes cell growth, survival and 
differentiation (Iqbal & Iqbal, 2014). 
 
There are two hypotheses explaining the association between estrogen and breast cancer: 
1) The binding between estrogen and ER enhances cell proliferation of mammary cells, and in-
crease in cell division and DNA synthesis elevates the risk for replication errors that may result in 
mutations (Deroo & Korach, 2006). 
2) Estrogen metabolism leads to the production of genotoxic byproducts that could damage DNA, 
leading to point mutations (Deroo & Korach, 2006). The link between estrogen and breast cancer 
may explain why breast cancer occurs 100 fold more frequently in women than men because of 
their higher estrogen levels (Santen, Yue, & Wang, 2014). The breast cancer incidence increases 
with age but slow down at age 50 which is the average age of menopause, which indicates that fe-
male reproductive hormones are involved in the breast cancer risk. 
Breast carcinomas are classified into four subtypes (figure 1.2) according to which receptors they 
express and whether they are associated with low or high amounts of the Ki-67 antigen. Ki-67 is a 
protein associated with cell proliferation (Lumachi et al., 2013). 
The four subtypes: 
1)      Luminal A breast carcinomas represents 50-60 % of all breast cancers (Lumachi et al., 
2013). Patients with this type of cancer have a good prognosis (Eroles et al., 2012). 
2)      Luminal B have a more aggressive phenotype than luminal A and makes up 10-20 % of all 
breast cancers. The difference between luminal A and B is that luminal B has an increased 
expression of proliferation genes (Lumachi et al., 2013). 
3)      Non-luminal, with HER2 overexpression (HER2+): this type of breast cancer has an over-
expression of HER2 and genes associated with the HER2 pathway. Non-luminal with HER2 
expression represent 15-20 % of all breast cancers (Eroles et al., 2012). 
4)      Basal-like tumors represent 10-20 % of all breast cancers. They do not express the HR and 
HER2. They are similar to triple-negative breast cancer but the concordance between these 
two subtypes is not 100 %. This type of breast cancer have a poor prognosis and are very 
aggressive (Eroles et al., 2012). 
The knowledge of these subtypes can tell which patients that will benefit from hormonal or cytoxic 
therapy (Eroles et al., 2012). 
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Figur 1.2 (Lumachi et al., 2013) 
2.1 Cholesterol 
Cholesterol is a sterol; a structural lipid with a steroid nucleus, and it is the major sterol in animal 
tissue (Nelson & Bulun, 2001). It is a component in the lipid membranes of the cells and the precur-
sor for steroid hormones, bile salts and various specialized molecules (Widmeier et.al. 2014) figure 
2.1 
2.2 Structure 
 
Figure 2.1 shows molecular structure of cholesterol (Nelson & Cox, 2013). 
 
The hydrophobic steroid nucleus and alkyl sidechain with the polar head makes cholesterol amphi-
pathic, which is a common trade for the membrane lipids. The steroids derived from cholesterol are 
missing the alkyl side chain that binds to the steroid nucleus. 
2.3 Synthesis 
All mammalian cells can synthesize cholesterol, but the synthesis is regulated by dietary cholesterol 
so that the plasma cholesterol stays somewhat stable. The homeostasis of plasma cholesterol is 
mainly controlled by the liver, which can both deliver cholesterol to the blood stream and remove it 
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(note that only liver cells and the cells lining in the gastrointestinal tract secrete cholesterol into the 
blood (Widmeier et al., 2014)). The regulation happens via a negative feedback on the enzyme 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase which is inhibited when the plasma 
cholesterol increases and is released from inhibition when the plasma cholesterol decreases (Nelson 
& Cox, 2013; Widmeier et al., 2014). Excess cholesterol extracted from the blood is also secreted to 
the bile to maintain homeostasis (Widmeier et al., 2014). 
 
Cholesterol’s precursor is acetate and the synthesis happens in four stages (Nelson & Cox, 2013): 
I: Acetate → mevalonate 
This step consists of two condensations; from 2 acetyl-CoA to acetoacetyl-CoA, catalyzed by ace-
tyl-CoA acetyl transferase (CoA-SH), which condenses with a third acetyl-CoA to HMG-CoA, 
catalyzed by HMG-CoA synthase (Nelson & Cox, 2013). 
A third reaction reduces HMG-CoA to mevalonate, this reaction is catalyzed by HMG-CoA reduc-
tase. 
 
 
Figure 2.3.1  shows the conversion of acetate to melanovate. 
(http://chemistry.umeche.maine.edu/CHY431/Cholest2.html) 
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II: Mevalonate → 2 activated isoprene 
First mevalonate is phosphorylated in two steps catalyzed by three different enzymes: mevalonate 
5-phosphotransferase, phosphomevalonate kinase and pyrophosphomevalonate decarboxylase; the 
intermediates are 5-phosphomevalonate, 5-pyrophosphomevalonate and 3-phospho-5-
pyrophosphomevalonate. The next step is a decarboxylation of 3-phospho-5-
pyrophosphomevalonate to 3-isopentenyl pyrophosphate, catalyzed by pyrophosphomevalonate 
decarboxylase. An isomerization of 3-isopentenyl pyrophosphate, catalyzed by isopentenyl pyro-
phosphate (IPP) isomerase, then creates an equilibrium between 3-isopentenyl pyrophosphate and 
dimethyallyl pyrophosphate. 
 
Figur 2.3.2“Mevalonate → 2 activated isoprene “ (modified from 
http://www.chembio.uoguelph.ca/educmat/chm452/lectur16.htm) 
 
III: 6 activated isoprene units → squaline 
In this step isopentenyl pyrophosphate and dimethylallyl pyrophosphate condense head-to-tail 
where one pyrophosphate is displaced, and forms the intermediate geranyl pyrophosphate (GPP), 
which in the same way condenses with another isopentenyl pyrophosphate to form another interme-
diate; farnesyl pyrophosphate (FPP). Squaline is formed when two FPPs condense head-to-tail and 
in the same process, FPP loses both pyrophosphate groups. 
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Figur 2.3.3 shows the conversion of activated isoprene units to farnesyl pyrophosphate 
(http://www.chembio.uoguelph.ca/educmat/chm452/lectur16.htm) 
 
IV: Squaline → four-ring steroid nucleus 
In this step squaline monooxegynase adds one oxygen atom to the end of the squaline chain to form 
squaline2,3-epoxide, which in turn undergoes a cyclization that results in lanosterol. Lanosterol is 
then, by multiple steps that are not going to be explained in this report, finally converted into cho-
lesterol. 
2.4 Functions 
Cholesterol has various, different functions in the human body. The main function relevant for this 
report is that cholesterol is a precursor for steroids, as androgens are converted to estrogens (Nelson 
& Cox, 2013). 
2.5 Transport within the body 
Many cells use cholesterol, but they only synthesize little themselves. Due to this, cholesterol is 
transported through the blood by various different transport proteins; chylomicrons, very-low-
density lipoproteins (VDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL). 
LDL is the main cholesterol carrier and is responsible for delivering cholesterol to cells throughout 
the body. LDL binds to membrane receptors and is then absorbed into the cell via endocytosis. Cho-
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lesterol, bound to LDL, is simply called LDL-cholesterol (LDL-C) (Widmeier et al., 2014). At the 
target cells LDL-C binds to receptors and is absorbed through the cell membrane by receptor-
mediated endocytosis where it is stored in non-membrane bound lipid droplets. It is released as free 
cholesterol by cholesterol esterase when the cell is stimulated in its use of cholesterol (Widmeier et 
al., 2014). 
HDL does the opposite and transports excess cholesterol in the blood to the liver, that metabolizes 
the excess cholesterol into bile salts. HDL also transports cholesterol to steroid producing endocrine 
cells, but. The main transport is to the liver (Widmeier et al., 2014). 
3.1 Estrogen Structure 
Estrogen is a naturally occurring steroid hormone, which functions as the primary female sex hor-
mone. There are three classes of estrogen: estrone (E1), 17β-estradiol (E2), and estriol (E3) 
 
Figure 3.1.1 “Estrogen types”, all derived from cholesterol (Nilsson et al., 2001). 
(http://www.blurrent.com/article/26-intriguing-facts-that-you-didn-t-know-about-estrogen-). 
 
Estrogen is secreted in large amounts from the ovaries (Nilsson et al., 2001). Estradiol is the pre-
dominant estrogen in women in the plasma. Estradiol is primarily produced in the ovaries and is 
called estrogen, even though estrogen counts all three types (Nilsson et al., 2001). Throughout the 
rest of the report it will be referred to as estrogen, when it is not specified. Estrone is also produced 
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in the ovaries, and estriol is mostly produced in pregnant women in the placenta (Nilsson et al., 
2001). In postmenopausal the estrogen production primarily takes place in the peripheral tissue (ad-
ipose tissue and skin). All three types of estrogen are produced from androgens (androstenedione or 
testosterone) by aromatase (Nilsson et al., 2001). 
 
3.2 Synthesis from cholesterol 
Estrogen is synthesized from cholesterol in several steps. In this chapter is a summary in five steps: 
I: Cholesterol pregnolone 
Within the inner mitochondrial membrane in steroid synthesizing tissue, cholesterol is converted to 
pregnenolone. This happens via, a hydroxylation sequence catalyzed by the enzyme cytochrome 
P450scc (CYP11A1) via the mechanism shown in fig 3.2.1 where the side chain of cholesterol is 
cleaved (Tuckey, 2005). 
 
 
 
fig. 3.2.1 “Cholesterol side chain cleavege” 
(http://chemistry.gravitywaves.com/CHE452/21_Adrenal%20Steroid17.htm - 7/4-2015; Tyckey, 
2004) 
II: Pregnolone   progesterone 
Pregnenolone is then converted into progesterone by type 1 3-hydroxysteroid 
dehydrogenase           (3-HSD) (Tyckey, 2004). 
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Figure 3.1.2 “conversion of pregnenolone to progesterone” (Yoshimoto & Auchus, 2014). 
 
III: progesterone    androstenedione 
Androstenedione is derived from progesterone via hydroxylation catalyzed by the enzyme 
CYP17A1. 
 
Figure xx “progesterone to adrostenedione” (Porubek, 2013) 
 
IV: Androstenedione to  testosterone 
Adrostenedione is then reduced to testosterone by 17-hydroxysteroid dehydrogenase (17-HSD) 
(Nelson & Bulun, 2001) : 
 
 
V: Androstenedione   estrone & testosterone   estradiol 
Androstenedione and testosterone are secreted in small amounts by the ovaries and in larger 
amounts by the adrenal cortex (Nelson & Bulun, 2001), and some of these are converted to estrogen 
in other organs than the ovaries, such as adipose tissue (Nelson & Bulun, 2001). 
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Aromatization of androgens is the primary mechanism of estrogen production in postmenopausal 
women (Nelson et al, 2001). 
 
Figure x.x “aromatization of androstedeione and testoterone” 
https://www.staff.ncl.ac.uk/i.r.hardcastle/antiendocrine.html 
The androgens used in this mechanism are primarily circulating androstenedione from the adrenal 
cortex, which is converted into estrone. Estrone is weakly estrogenic and is locally reduced to estra-
diol for more estrogen activity. This reduction can cause cancer in postmenopausal women (Nelson 
et al, 2001). 
In premenopausal women the estrogen production is fluctuating according to the menstruational 
cyclus (Widmeier et al.2014), but in postmenopausal women the estrogen production is constant. As 
a consequence of this, the breast tissue in these women is continuously exposed to estrogen (Nelson 
et at, 2001). However, the estrogen level is reduced in postmenopausal women whom’s mean serum 
estrogen level is 25 pmol/l which is synthesized mainly in other tissues than the glandular, whereas 
in premenopausal women the mean serum estrogen level is 400 pmol/l  which is synthesized pri-
marily in the ovarians (Zidan, el al., 2010). 
4.1 Estrogen receptors 
There are two types of estrogen receptors, estrogen receptor (ER) and estrogen receptor (ER), which 
belongs to the steroid superfamily of nuclear receptors (Nilsson et al, 2001). They have three inde-
pendent but interacting functional domains: the NH2-domain, the DNA-binding domain (DBD), and 
the COOH-terminal, also called the ligand-binding domain (LBD).  The NH2-domain functions in-
dependently of ligands. The DBD plays an important role in receptor dimerization and binding of 
receptors to specific DNA sequences. The COOH-terminal is responsible for the change in confor-
mation when ligands bind to an estrogen receptor and mediates receptor dimerization, nuclear trans-
location and transactivation of target gene expression. It is in the NH2-domain the difference be-
tween ER and ER is found. In ER the NH2-domain is very active in the stimulation of reporter-gene 
 
 
Page 17 af 53 
 
expression from a variety of estrogen response element (ERE)-constructs in different cell lines but 
in ER the NH2-domain is almost not active in this stimulation (Nilsson et al, 2001). 
Both ERs have two transcriptional activation domains AF1, located in the NH2-domain and AF2 
located in the COOH-terminal. (Edwards & Boonyaratanakornkit, 2003). The core of the COOH-
terminal is inactive as a transcription factor, but sufficient for mediating many rapid estrogen re-
sponse pathways (Edwards & Boonyaratanakornkit, 2003). 
It is commonly known that it is the ER α that is responsible in the development of breast cancer 
(Wang & Yin, 2015), and thus only this receptor will be discussed further. 
4.2 Function 
ER are located in the nucleus and estrogens diffuse freely over the cell walls (Deroo & Korach, 
2006). The major actions of estrogens is the slow (within hours) direct transcriptional regulation of 
specific gene networks (Edwards & Boonyaratanakornkit, 2003). The estrogen-ER complex binds 
directly or indirectly to ERE-sequences, through protein-protein interactions with activator protein 1 
(AP1) or specificity protein 1 (SP1) sites in the promotor regions of estrogen-responsive genes 
(Deroo & Korach, 2006). These interactions result in recruitment of coregulatory proteins (coactiva-
tors and -repressors) to the promoter; increased or decreased mRNA levels and associated increased 
or decreased protein production and other physiological responses, depending on the cell (Deroo & 
Korach, 2006). These are slow mechanisms that happen over the course of hours. Estrogens can 
also act more swiftly (within seconds or minutes) by not travelling all the way to the nucleus. It can 
bind either to ERs located in or adjacent to the plasma membrane or to non-ER estrogen-binding 
proteins associated with the plasma membrane (Figure 4.2.1) (Deroo & Korach, 2006). These inter-
actions result in cellular responses such as increased levels of Ca
++
 or NO and activation of kinases. 
The rapid non-transcriptional activation of various signaling molecules and signal transduction 
pathways are independent of the synthesis of new mRNA and associated protein synthesis (Edwards 
& Boonyaratanakornkit, 2003).[5] [6]  ERs are, as other steroid receptors, latent activators that re-
quire ligand binding for activation (Edwards & Boonyaratanakornkit, 2003). Binding of a ligand to 
ER changes the rate of transcription of estrogen-regulated genes. (Nilsson et al, 2001). 
In the nucleus, ER mediates estrogen effects by different interactions with DNA, dimerization with 
other receptors, recruitment and interaction with transcription factors such as coactivators, and for-
mation of preinitiation complex (Nilsson et al, 2001; Deroo & Korach, 2006). These DNA interac-
tions happen through AF1 and AF2 (Edwards & Boonyaratanakornkit, 2003). It is unclear if the 
non-ER estrogen-binding proteins are unrelated to the ERs or whether they are a subpopulation to 
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the different associates of ERs, which associates with the plasma membrane to mediate rapid non-
transcriptional actions of estrogen (Edwards & Boonyaratanakornkit, 2003). 
The response to estrogen is dependent on the specific tissues and cells (Edwards & 
Boonyaratanakornkit, 2003). 
 
Figure 4.2.1 “Estrogen’s binding with ER and non-ER” (modified from Deroo & Korach, 2006) 
5.1 Letrozole and its structure 
Letrozole is a nonsteroidal, third generation, type II aromatase inhibitor (AI), where the type of the 
AI refers to the biological functions (Smith & Dowsett, 2003; (Scott & Keam, 2006)). Letrozole 
function as a competitive inhibitor and is highly selective in its inhibition (Scott & Keam, 2006). 
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5.2 How does letrozole function – its role in breast cancer? 
AIs function by inhibiting or inactivating aromatase, the enzyme synthesizing estrogen from choles-
terol, or more specifically estradiol and estrone from the androgens testosterone and androstenedi-
one, respectively, and thus decreasing plasma estrogen levels (Smith & Dowsett, 2003). Aromatase 
belongs to the superfamily of the cytochrome P450 enzymes and is the rate-limiting step in the syn-
thesis of estrogen (Smith & Dowsett, 2003). The nitrogen-containing parts of letrozole (Bhatnagar, 
2007)bind reversibly to the heme group of the cytochrome P450 subunit of the aromatase enzyme 
(Smith & Dowsett, 2003).  By inhibiting aromatase, letrozole inhibits estrogen biosynthesis 
throughout the entire body (Scott & Keam, 2006), but it has no effect on the synthesis of certain 
other hormones, such as thyroid hormones (Haynes et al., 2003) 
Estrogen is believed to initiate and promote ER+ breast cancer (Yager & Davidson, 2006). 
Reduction of estrogens in the breast, by inhibiting aromatase (Smith & Dowsett, 2003), functions as 
prevention and treatment of breast cancer (Jeon et al., 2009). 
In postmenopausal women with large primary breast cancer, treated neoadjuvant with AIs, it has 
been shown that letrozole profoundly inhibits in situ aromatase activity and thus it is reducing en-
dogenous estrogen within the breast (Miller, 1999). 
In a review, the use of AIs for treatment of postmenopausal endocrine-responsive breast cancer in 
the metastatic, adjuvant, and preoperative settings is processed (Briest & Davidson, 2007). AIs are 
widely accepted as treatment in postmenopausal women and are standard-care in first-line therapy 
of breast cancer (Briest & Davidson, 2007). 
5.3 The use and potency of letrozole 
Letrozole is used as first-line therapy and extended adjuvant therapy in postmenopausal women 
with hormone-responsive, early breast cancer (Scott & Keam, 2006). Breast cancer is the most 
common type of cancer in women in Western countries, especially in postmenopausal women 
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(Tobias, 2004). Estrogen is well-established as an important agent in development of breast cancer, 
as almost 70 % of postmenopausal having hormone-receptor positive (HR+) tumors (Tobias, 2004). 
Thus components reducing estrogen synthesis can be used in the treatment of HR+ breast cancer 
(Baum, 2004) because the stimulation of the estrogen-dependent tumors is reduced (Michaud, 
2005). Letrozole significantly inhibits proliferation in estrogen-dependent tumors independent of 
human epidermal growth factor receptor (HER) status (Ellis et al., 2003). 
5.4 Compared to other AIs and tamoxifen 
Letrozole and other AIs have shown to be more effective than tamoxifen in the endocrine treatment 
of breast cancer (Smith & Dowsett, 2003). But tamoxifen has other beneficial effects. Tamoxifen 
functions as an agonist and thus it reduces the lipid levels (Bell et al., 2012). 
The antitumor effects of letrozole were demonstrated and a prediction of letrozole’s superiority to 
tamoxifen was made as well as predictions of letrozole’s possibly superiority to other AIs. It was 
shown that letrozole is highly potent and selective of intracellular aromatase with an almost com-
plete suppression of all body aromatization of estrogen (Bhatnagar, 2007). Furthermore letrozole 
was shown to be more potent that tamoxifen and to be the most potent AI of the third generation 
AIs in regards to both early breast cancer (EBC) and advanced breast cancer (ABC) (118, 123) 
(Bhatnagar, 2007). 
A recapitulation of the current role of AIs and their potential for clinical use was made (Smith & 
Dowsett, 2003). It seems that letrozole is convincingly more potent of the AIs (Smith & Dowsett, 
2003). 
Successful translational research has shown that of the AIs the third generation is more efficient 
than both first and second generation AIs (Lønning, 2004). 
It is unclear if one third generation AI is better than the other (Briest & Davidson, 2007). All third 
generation AIs are effective in regard to reducing breast cancer recurrence but in some cases no 
overall superiority to tamoxifen has been shown (Briest & Davidson, 2007). In other cases, letro-
zole have been shown to cause a greater reduction in breast cancer recurrence (disease-free surviv-
al) in women with breast cancer compared to tamoxifen Figure x.x (BIG 1-98 Collaborative Group, 
2005). Furthermore it has been shown in the follow-up study (Regan, 2012) on BIG 98-1 Collabora-
tive Group that letrozole use can lead to hypercholesterolemia (Keating, 2009). 
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Figure x.x shows the disease-free survival among breast cancer patients treated either with tamoxi-
fen or letrozole (Regan et al., 2011). 
5.5 Effect on estrogen and lipid levels 
In a prospective study the effect of letrozole on plasma lipids, triglyceride lipase, and estradiol lev-
els in women with metastatic breast cancer was evaluated (Zidan et al., 2010). Total cholesterol and 
HDL-C was insignificantly increased after three months but returned to baseline values after six 
months (Zidan et al., 2010). Also LDL-C increased insignificantly but after six months, this value 
returned to baseline value after 12 months (Zidan et al., 2010). The estradiol value decreased from 
44 pmol/l to less than 18 pmol/l before six months, thus indicating that letrozole has a safe effect on 
lipids and triglyceride lipase (Zidan et al., 2010). 
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Letrozole has shown no significant alteration but small increases of total serum cholesterol, LDL-
cholesterol, and triglyceride levels after up to 36 months treatment among 347 participants (Wasan 
et al., 2005). But the more comprehensive study (BIG 1-98 Collaborative Group, 2005) which en-
compasses 8010 participants, showed the opposite in approximately 30 % of the patients (BIG 1-98 
Collaborative Group, 2005). 
5.6 Short- and long-term effects 
Long-term effects of profound suppression are unknown and careful monitoring for bone deminer-
alization should be made (Smith & Dowsett, 2003). 
Furthermore AIs are believed to play a key role in future adjuvant breast cancer therapy but lack of 
cross-resistance between steroidal and nonsteroidal AIs still needs to be investigated (Lønning, 
2004). The importance of postmenopausal estrogen levels to subsequent breast cancer development, 
body mass index, and plasma estrogen correlation has been substantiated by the plasma estrogen 
levels, bone demineralization, and breast density (Lønning, 2004). (Meta-analysis of the above: 
body mass index, serum sex hormones, and breast cancer risk in postmenopausal women). 
Furthermore the long-term effects as bone demineralization, cardiovascular disease, and cognition 
still need to be evaluated (Briest & Davidson, 2007). Co-administration/drug-drug interaction of 
AIs has partly shown to affect some growth factors and their downstream products that interact with 
ER signaling (E-hypersensitivity, increase of signal transduction pathways, cross-talk between other 
signal transduction and ER pathways) (Briest & Davidson, 2007). 
Due to AIs’ inhibition of aromatase in every type of tissue, use of AIs could lead to a fear of bone 
loss and cognitive function, and thus a tissue-specific inhibition of aromatase expression is desirable 
and, as it turns out, possible because of decrease of estrogen synthesis in the ovaries in postmeno-
pausal women (Simpson & Dowsett, 2002). In postmenopausal women estrogen is primarily local 
paracrine and intracrine, and tissue-specific promoters regulate each tissue (Simpson & Dowsett, 
2002). 
5.7 Pharmacokinetics of letrozole 
Letrozole is rapidly absorbed after ingestion (Simpson et al., 2004). At steady state letrozole has 
nonlinear pharmacokinetics (Femara, prescription) and is highly distributed in tissues (Sioufi et al., 
1997). Furthermore it is converted to its inactive metabolite by CYP3A4 and CYP2A6 isoenzymes 
and with cimetidine and warfarin co-administrations, no drug-drug interaction was found (Femara, 
prescription). But when letrozole is co-administered with tamoxifen the effect of letrozole is re-
duced (Femara, prescription). 
 
 
Page 23 af 53 
 
6.1 Statins 
Statins are cholesterol-lowering drugs used to reduce high cholesterol levels in the blood. Statins act 
as a strong competitive inhibitor with a 1.000-fold greater affinity to HMG-CoA reductase than 
HMG-CoA.  Statins inhibit HMG-CoA reductase in the liver by binding to its active site (Manu-
script, 2014), and thereby inhibit the conversion of HMG-CoA to mevalonate, used in the synthesis 
of cholesterol (figure 6.1.1) (Ahern et al., 2014). 
 
Figur x http://www.people.vcu.edu/~urdesai/intro.htm 
A resume of cholesterol biosynthesis and where statins inhibits it. Statins have a 1.000 greater affin-
ity for HMG CoA reductase than HMG CoA and inhibits the reduction of HMG CoA to molanovate 
by binding to HMG CoA redutase’s active site. 
Statins are used to treat familial hypercholesterolemia, atherosclerosis and other diseases resulting 
from elevated cholesterol levels (Nelson & Cox, 2013). The lowering of LDL-C leads to the upreg-
ulation of LDL-receptors (Wang et al., 2008) and is the primary pathway of clearing circulating 
LDL-C from the blood (Lagor & Millar, 2010). Beside statins’ cholesterol-lowering effects, (dos 
Santos et al., 2014) showed some association between LDL-C and cancer cell proliferation and mi-
gration. Statins may therefore contribute to the treatment of cancer. 
Observational studies and clinical trials of statin use and breast cancer risk, have shown diverse 
results; some show no association, while others show an increase in breast cancer risk while report a 
protective effect by the use of statins compared to those patients not using statins (Desai et al., 
2013). The most serious side effects by using statins are myopathy and rhabdomyolysis. It is as-
sumed that myopathy is caused by the inhibition of FPP, which is an intermediate for ubiquinone or 
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coenzyme Q10 (CoQ10) and is important in mitochondrial energy production in the electron 
transport chain (Marcoff & Thompson, 2007). The FPP inhibition leads to CoQ10 deficiency and 
may lead to mitochondrial dysfunctional (Marcoff et al., 2007). The minor side effects are nausea, 
gastrointestinal pain, constipation and dyspepsia (Wong, Dimitroulakos, (Wong, Dimitroulakos, 
Minden, & Penn, 2002)).      
Statins can be categorized as lipophilic or hydrophilic, they differ in their potency and solubility. 
Hydrophilic statins are more restricted to the liver where lipophilic statins easily can spread through 
extra hepatic tissues and therefor have greater potential to exert pleotropic effects (Ahern et al., 
2014). There are several different statins categorized as lipophilic: simvastatin, cerivastatin, pitavas-
tatin lovastatin, atorvastatin, fluvastatin and a few categorized as hydrophilic: pravastatin and rosu-
vastatin (Wong et al., 2002). The first natural statin discovered was mevastatin in 1976, but clinical 
trials in rats showed that mevastatin caused hepatocellular toxicity (Liao & Laufs, 2009). In 1979 
lovastatin, a more potent inhibitor and not causing hepatocellular toxicity in rats, was isolated from 
Aspergillus terreus (Liao & Laufs, 2009). Therefore lovastatin became the first natural statin drug 
for human use (Liao & Laufs, 2009). Other natural statins are simvastatin and pravastatin. Statins 
are administered as active hydroxy acids except for simvastatin and lovastatin, which are consumed 
as lactones (inactive form) (Wong et al., 2002) pro-drugs (Gazzerro et al., 2012) and metabolized in 
the liver by CYP enzymes to active and inactive metabolites. Simvastatin (figure 6.1.2) the most 
prescribed statin is metabolized by CYP3A4 to beta-hydroxyacid, which is the active form of 
simvastatin. All statins share HMG-like moiety and can therefore inhibit HMG-CoA reductase by 
similar mechanisms (Liao & Laufs, 2009). The doses range between 5-80 mg/day for all statins and 
are consumed orally (Gazzerro et al., 2012). 
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Figur 6.1.2 http://pubchem.ncbi.nlm.nih.gov/compound/simvastatin 
The molecular structure of simvastin. 
6.2 Pleiotropic effects 
The inhibition of HMG-CoA reductase leads not only to inhibition of cholesterol synthesis but also 
to the inhibition of downstream intermediates of the mevalonate (MVA) pathway, such as isopre-
noids, squalene, steroids and others (Liao & Laufs, 2009). The inhibition of these other metabolites, 
leads to cholesterol-independent effects (pleiotropic effects), such as improvement of endothelial 
function, decreasing oxidative stress and enhancing the stability of atherosclerotic plaques (Liao & 
Laufs, 2009).  These effects will be explained more detailed later in this chapter 
6.3 Statins as a possible chemotherapeutic agent 
The MVA pathway is responsible for synthesizing all mammalian isoprenoids. Isoprenoids in the 
MVA pathway such as FPP and geranylgeranyl pyrophosphate (GGPP) are metabolites important 
for post-translational prenylation of GTP-binding proteins (GTPase). There are many differ-
ent/similar GTPases; Rac, Rho, Ras are some of them. GTPases acts as molecular switches control-
ling multiple pathways, cell functions, proliferation and apoptosis (Liao & Laufs, 2009) (Gazzerro 
et al., 2012).  GTPases cycle between their inactive, GDP bound state and active, GTP-bound state 
and is depended on prenylation before they can exists in their active form (Wang et al., 2008). 
Statin use therefore leads to the accumulation of inactive GTPases (Liao & Laufs, 2009). The Ras 
proteins (H-Ras, K-Ras, N-Ras) also known as the Ras oncogene superfamily, depends on farnesyl-
ation to become active where Rho proteins (RhoA/B/C. Rac-1 and Cdc42) depends on geranyl-
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geranylation. Activation of Ras proteins, in an inappropriate way, has a key role in proliferation, 
malignant transformation and signal transduction (Wang et al., 2008). The inhibition of HMG-CoA 
reductase and depletion of FPP and GGPP may therefore result in chemoprevention (Ahern et al., 
2014) which leads to the possibility of using statins as a chemotherapeutic agent (Wong et al., 
2002).   
6.4 Endothelial dysfunction 
Endothelial dysfunction is a result of hypercholesterolemia (Liao & Laufs, 2009). Some of the side 
effects of endothelial dysfunction are impaired synthesis, activity and release of endothelial-derived 
nitric oxide (NO) (Liao & Laufs, 2009). Endothelial-derived NO is important for vasodilation, the 
decreasing of vascular smooth-muscle proliferation, and inhibition of platelet aggregation (Liao & 
Laufs, 2009). Endothelial dysfunction is one of the earliest events that leads to atherosclerosis and 
studies suggest that endothelial function could be restored by statins (Liao & Laufs, 2009). Statin 
increase the NO production, by inhibition of GGPP or RhoA, resulting in upregulation of eNOS 
expression by prolonging eNOS mRNA half-life (Liao & Laufs, 2009). 
6.5 Atherosclerotic plaques 
Atherosclerosis is the formation of plaques in the blood vessels and is a type of cardiovascular dis-
ease (Reddy & Seshaiyer, 2015). Atherosclerosis starts when LDL-C accumulates in the intima of 
artery walls. In the arterial intima LDL-C undergo oxidation and becomes ox-LDL-C, which pro-
mote inflammatory processes (Wang et al., 2008), that causes endothelial cells to release monocyte 
chemoattractant protein (MCP-1). MCP-1 then attracts monocytes to the arterial intima where it 
matures to macrophages, which in turn engulfs the ox-LDL-C. This makes them lose motility and 
turns the macrophages into foam cells. Foam cells sends positive feedback that result in the releas-
ing chemokines, which leads to recruitment of more macrophages. The macrophages release growth 
factors that stimulates the smooth muscles cells in the media, causing them to migrate into the arte-
rial intima.  When foam cells and smooth muscle cells die in the intima, they release their lipid con-
tents, which forms a lipid core.  A healing process against lipid core is the formation of a fibrous 
cap which creates plaques named thin-capped fibroatheromas. Macrophages release matrix metallo-
proteinases that will degrade the plaques and eventually lead to rupture (Reddy & Seshaiyer, 2015). 
This results in the contact between lipid core and blood, which in turn results in thrombosis. Statins 
contribute to plaque stability by lowering lipid concentration (Liao & Laufs, 2009). 
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6.6 Inhibition of ROS generation 
NADPH oxidase complex is the collection of proteins that donate an electron from NADPH to oxy-
gen and produce superoxide.  The complex needs activation by GTPases Rac1 and rap1a. As men-
tioned before, statins inhibit isoprenoids, and Rac and rap1a therefore does not get activated (Wang 
et al., 2008). 
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Analysis 
BMI, estrogen and breast cancer risk 
In this part of the analysis the meta-analysis “Body Mass Index, Serum Sex Hormones, and Breast 
Cancer Risk in Postmenopausal Women” is analyzed to assess some possible factors in the relation-
ship of BMI, estrogen and breast cancer. The different studies in the analysis are mainly commented 
on, on the basis of their abstracts and the information avaiable in the meta analysis. Two of the stud-
ies are analyzed further to see which factors may have contributed to the conclusion. 
In a meta-analysis (Key et al., 2003), which was conducted by the Endogenous Hormones and 
Breast Cancer Collaborative Group (EHBCCG), it was investigated whether the increased risk of 
breast cancer caused by increased body mass index (BMI) could be associated with increased estro-
gen levels. The meta-analysis consists of eight prospective studies selected on specific terms, in-
cluding: 
●       The data encompassing endogenous hormones and breast cancer risk using prospectively 
gathered blood samples from postmenopausal women (Key et al., 2003). 
●       Data on reproductive and anthropometric factors 
●       Date of diagnosis of case patients, date of birth, date of blood collection 
●       Cohort study where blood samples were collected from healthy women who were fol-
lowed afterwards to identify breast cancer subjects 
●       None of the women used hormone replacement therapy or other exogenous sex hormones 
at time of blood collection 
●       Data on concentrations of the hormones were retrieved from blood samples 
●       All women were postmenopausal 
●       The studies were nested which means control subjects were paired with case subjects after 
diagnosis 
The studies included in the meta-analysis have been examined before in another paper by EHBCCG 
to investigate the overall associations of sex-hormones with breast cancer risk in postmenopausal 
women. Common criteria for all the women in the studies included in this meta-analysis were data 
on BMI and prediagnostic estradiol levels which was available for 624 case subjects and 1669 con-
trol subjects. Additionally, the studies provided data on  free estradiol, non-sex hormone-binding 
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globulin-bound (SHBG) estradiol (free plus albumin-bound estradiol), estradiol (total), estrone, 
estrone sulfate, androstenedione, dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate 
(DHEAS), testosterone but these were available for fewer participants (Key et al., 2003). Further-
more height, weight, date of diagnosis of case patients, date of birth, and date of blood collection 
was part of the inclusion criteria. Women fulfilling these five criteria were eligible. The studies in-
cluded women with both normal weight, overweight and obese women, according to WHO’s defini-
tion of BMI
[3]
 which make it representative for a larger population of women, and makes it easy to 
compare to for other studies. 
The characteristics of the eight studies can be seen in table x.x 
 
Table x.x “Characteristisc and body mass index by case-control status and study” (Key et al, 2003) 
For the studies that weren’t nested, this was done subsequently by EHBCCG within the cohort and 
control groups to make all eight studies comparable (Key et al, 2003). This means that the matching 
of control and case subjects were not as precise as the nested ones, as good matches were not al-
ways possible within the cohort. In one of the studies included in the meta-analysis (Berrino et al, 
1996) it was proved that matching case and control subjects was important for controlling undesired 
variability. Only 4 out of 8 studies were nested. This means that the studies that were not nested 
contributes to an uncertainty when adjusting for age, menopausal status and time for the collection 
of blood samples. As half of the studies contributes to this, there might be some some undesired 
variabilities that are not accounted for. 
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Even though all studies adjusted for age when comparing hormone levels, the age did not seem to 
affect the amount of years from registration to diagnosis. This tendency can be seen in table x.x as 
the two groups with the lowest mean age has the next highest amount of years to diagnosis 
(Guemsey, UK) and the lowest amount of years to diagnosis (NYU WHS, USA). 
The association with BMI was not assessed in the abstract of the studies involved in the meta-
analysis, but anthropometric data was available in them, as that was one of the inclusion criteria for 
the meta analysis. In the two studies that is analyzed later in this chapter, BMI was not found to 
have a significant effect on the relative risk for breast cancer, but it is also mentioned that this might 
be due to lack of statistical power (Berrino F., 1996). Information about BMI was gathered both by 
self report and measured by trained staff at the institutions were the blood samples were taken (see 
appendix 1). The BMI from the SOF study is the least precise data, as the subjects (both case and 
control) who were at least 62 years old, had to report their height from when they were 25, which is 
even less precise than relying on women who had to report their current height. This was done to 
asses the problem that some of the women could have experienced osteoporotic height loss after 
vertebral fractures. A similar situation asserted itself in the Nurses’s health study, as weight and 
height was reported as of the age of 18. Self-reported information about BMI is not as precise as if 
it was measured by the staff at the same time as the blood sample, because subjects might report it 
just by memory or might not have proper equipment and might report numbers that are rounded up 
or down.  In the case of the SOF and Nurses’s health study, the BMI from when subjects were 
younger is not representative for a woman in her 60’es or 70’es (mean age as seen in table x.x.), not 
to mention that at that time, they were most likely premenopausal. 
That the effect of BMI on BC risk was not found significant in Berrino et al. (1996), possibly due to 
lack of statistical power, do not need to affect that the Key et al. (2003) found an association, as 
they had access to all the data from the included studies, which could contribute to the statistical 
power that Berrino et al (1996) was lacking. 
The association with BMI and breast cancer was made as in “indirect link” as it was compared to 
the hormone levels and a positive association was found. This can be seen in figure x.x where BMI 
is compared to the mean concentration of estradiol (to the left) and the relative risk for developing 
breast cancer (on the right). 
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Figure AN.1. 
 
Overall the case subjects had higher BMI than the control subjects (26,5 relative to 25,8). The two 
studies with the lowest mean BMI (Ranco Bernado, USA & RERF, Japan) have the largest amount 
of years from registration to diagnosis. This fits with the hypothesis that high BMI is a risk factor, 
but is not commented in the meta-analysis. 
The relative risk according to BMI was calculated relative to category 1 (<22,5kg/m
2
) 
In this report only results for estradiol is shown, as that is the only one all the studies reported. Also 
it is the only hormone of interest to the group as, out of this selection of hormones, only estrogens 
are of relevance to the estrogen receptors and through them are of relevance to ER+BC.[9]  Also 
estradiol is the most interesting one as the production of it increases with the adipose tissue in 
postmenopausal women and therefore is assumed to increase with BMI. 
Conclusion summary for the meta-analysis regarding BMI, estrogen, and breast cancer risk 
After adjusting for free estradiol, other estrogens, and risk factors the results still suggested that the 
association between increased breast cancer risk with increased BMI was the result of increased 
estrogen (Key et al., 2003). 
Studies have shown positive association between estrogen levels and breast cancer risk and high 
BMI is considered a general risk factor for postmenopausal women. On top of that increase in BMI 
is positively associated with increased estrogen levels (see figure AN.1) . 
The group has further more analyzed  two of the studies included in the meta-analysis (Hankinson 
et al., 1998); Berrino et al, 1996)  to see which factors may have contributed to the conclusion and 
especially how the studies assessed the connection with BMI. 
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The two studies were selected because they represented self-reported BMI and measured BMI thus 
could contribute to understand how this was different and were the largest studies in these two cate-
gories. A table of the characteristics for the two studies can be seen in appendix 2. 
The cohort in Hankinson et al (1998) was almost 3 times as large as the cohort in Beronni et al. 
(1996). This was adjusted for in Key et al. (2003) by working with mean values and pooled values 
as all the cohorts were different size. All the different studies were large enough to asses an actual 
effect, but the studies with a case group of less than 50 subjects could be argued to only being hy-
pothesis generating due to lack of cases to show an effect. 
As mentioned before, the matching of case and control was important to avoid undesired variabili-
ties. Beronni et al. (1996) had better matches over all, except for date of blood sample, which was 
the same day in Hankinson et al (1998). Both have good matches and opposite to the four studies in 
the meta-analysis which are not nested, possible contributes to better comparability between hor-
mone levels, BMI and relative risk. 
The subject information for all the women in the cohort in the Barroni et al. (1996) study was re-
trieved by trained nurses, including check for diagnosis. In the other study informations were re-
trieved, along with blood samples, from self-report. The interesting thing is that in this study the 
cohort consists of nurses, who assumably is more qualified to give precise information due to their 
profession, than the cohort from Italy, whom’s professions were not taken into account. This makes 
the information more comparable than if it had been a cohort not consisting of nurses that had to 
self-report all the information. 
Both studies had blood samples traveling: samples in Hankinson et al (1998) traveled from wherev-
er the nurses got their blood samples taken, and samples in Barroni et al. (1996) from the other in-
stitute, so this shouldn’t contribute to an uncertainty, but as it is not recorded how far the Hankinson 
et al (1998)’s samples had been moved other than it was within 26 hours, it is not sure. 
The blood samples were stored on in a freezer for a different amount of time in the two studies.That 
it is not recorded for how long the individual blood samples had been stored in the freezer has no 
effect on the hormone levels. This was tested by Borrino et al (2006) and the levels were stable 
even after 3 years of storage. On the contrary that it made it possible to asses the blood samples 
more or less at the same time, with the same equipment, by the same staff makes the samples more 
comparable. The samples from Hankinson et al. (1998) was analyzed in three batches with 2 years 
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in between, this could make a difference if the same equipment was not used, but according to the 
stability of the hormones in the blood samples, it should not make a difference in comparability. 
Metabolic syndrome and breast cancer risk 
In a meta-analysis (Laezza et al., 2010) the potential association between metabolic syndrome (MS) 
and postmenopausal breast cancer risk was investigated by reviewing and analyzing nine epidemio-
logical studies published between 2009 and 2012. Four of these were prospective cohort studies, 
two were nested case-control, two were case-control, and one was a retrospective Japanese cohort 
study (Table). In total the articles encompassed 6,417 cancer cases and for the cohort studies the 
sizes ranged from 5,450 to 287,320 participants while the case-control studies’ control groups con-
sisted of between 261 and 4,082 participants. All included studies were human studies, and should 
either provide adequate data to estimate the risks or report the risk estimates themselves besides 
definition of the syndrome. The components of the syndrome considered in the meta-analysis were 
BMI/waist circumference, hyperglycemia, higher blood pressure, higher triglycerides, and LDL-C. 
Studies were excluded if not published as full reports. Inclusion criteria comprised quality of elec-
tion, comparability, exposure, and outcome of study participants (Esposito et al., 2013). Several 
data were extracted from each study, concerning name of the first author, year of publication, coun-
try where the study was performed, follow-up time, total number of individuals, number of cases, 
and risk estimates and 95 % confidence interval. Furthermore risk estimates for every single com-
ponent were collected and compared to risk estimates of the full syndrome within the same study. 
For all studies the heterogeneity was quantified to describe the total variation across studies for 
subgroups according to populations and definition of MS, and the quantification showed that the 
overall heterogeneity among the studies was high. Publication bias was examined and indicated by 
analysis and was made insignificant by exclusion of biased studies after sensitivity analysis. Lastly, 
tests to assess true statistical significance were performed (Esposito et al., 2013). 
In general, MS was associated with a 52 % increased risk for postmenopausal breast cancer, which 
changed a little depending on the populations and the definition of the syndrome but was significant 
irrespective of country. Separate and combined analyses were made in addition to sensitivity anal-
yses. Meta-regression, a permutation test, and regression asymmetry test were performed. On the 
basis of this, BMI, triglycerides, and HDL-C were analyzed and discussed in this meta-analysis 
among others. Furthermore these factors were examined and mentioned as risk estimates and it was 
concluded that increased BMI and decreased HDL-C were associated with increased postmenopau-
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sal breast cancer risk and that triglycerides were not associated with postmenopausal breast cancer 
risk, and that decreased HDL-C was associated with increased postmenopausal breast cancer risk. 
Overall the risk of postmenopausal breast cancer was moderately increased. Furthermore neither did 
increased BMI explain the risk that is related to the full syndrome nor did high levels of triglycer-
ides or decreased HDL-C individually. It is unknown if the risk conveyed by the full syndrome is 
greater than the components combined, which means that maybe some of the components of the 
syndrome combined equals the risk of the full syndrome. This meta-analysis is the first to evaluate 
the role of hypertension, high triglycerides, and low HDL-C in postmenopausal breast cancer risk. 
Letrozole and breast cancer risk 
A prospective study conducted by Zidan et al. (2010) investigated the association between letrozole 
and lipid profiles, trigylceride lipase, and estradiol plasma levels in women with metastatic breast 
cancer (MBC), each receiving letrozole 2.5 mg/day. Blood samples were collected at baseline, after 
three, six, and 12 months. The characteristics of the study are gathered in table x.x where it is com-
pared to another study by Bell et al. (2012). 
The other study (Bell et al., 2012) on the AIs’ (exemestane and letrozole) effect on the plasma lipid 
profile in postmenopausal women with breast cancer measured total cholesterol, HDL-C, LDL-C, 
and triglycerides before and after three months of treatment with either exemestane or letrozole. 
This was investigated due to AIs’ deprivation of estrogen which is known to affect lipid concentra-
tions and therefore cardiovascular disease. Furthermore postmenopausal women already have in-
creased risk of altered lipid profiles and cardiovascular disease and thus this population is important 
to examine (see Appendix 3). 
The duration of prior tamoxifen use was not taken into consideration during the analysis of the re-
sults, it was only considered if the patients had taken tamoxifen prior to AI treatment or not. 
In the study conducted by Bell et al. (2012) the blood samples were collected after 3 months of AI 
treatment. Compared to the other study (Zidan et al., 2010) and the “normal” AI treatment duration 
(which is 2-5 or more years), this is a rather short time of investigation. Furthermore the study of 
Bell et al. (2012) made a comparison of an entire cohort, an exemestane group, and a letrozole 
group on the basis of the baseline values and the values after 3 months treatment whereas Zidan et 
al. (2010) compared letrozole with letrozole on the basis of the baseline values, the values after 3, 6, 
and 12 months of letrozole treatment. Neither of the studies compare to a placebo or control group 
but to the baseline values. In the study by Zidan et al. (2010) the percentages for description of par-
 
 
Page 35 af 53 
 
ticipants are not calculated as it is in the study by Bell et al. (2012). In both studies a patient charac-
terization is made but it is not mentioned whether all these variables are taken into consideration or 
not. In Bell et al. (2012) a multivariate analysis was made, which showed that only baseline HDL-C 
was a significant predictor of the reduction in HDL-C following AI treatment. Also for exemestane, 
baseline HDL-C was an independent predictor. Both baseline LDL-C and prior use of tamoxifen 
were statistically significant predictors of change in LDL-C. This was also the case for letrozole 
(Bell et al., 2012). Furthermore the patients were stratified by prior use of tamoxifen but this did not 
affect the exemestane-induced reduction in HDL-C, but was partially responsible for observed ele-
vations in LDL for letrozole patients because only women that had used tamoxifen prior to the let-
rozole treatment experienced a significant increase in LDL-C (Bell et al., 2012). The change in 
LDL-C in the entire lipid analysis cohort was significantly associated with baseline TC, LDL-C, 
LDL/HDL-ratio, and prior use of tamoxifen (Bell et al., 2012). 
In patients receiving letrozole treatment no significant altering in HDL was shown (Bell et al., 
2012). The explanation could be that letrozole does not produce an androgenic metabolite that binds 
to the androgen receptor, which exemestane does. Additionally the exemestane group had a higher 
baseline value for HDL-C. 
The characterization is not completely similar in the two studies. The methods and statistics used by 
Zidan et al. (2010) are not very comprehensively described, and thus it is difficult to know what has 
been taken into account and what has not. The duration of the study of Bell et al. (2012) is 4 years 
in which the duration of the AI treatment is 2 years and for Zidan et al. (2010) it is 3 years but the 
duration of the treatment is “until disease progression”, which is not defined. Thus, due to the dura-
tion of the entire study of Zidan et al. (2010) being shorter that the duration of the entire study of 
Bell et al. (2012), the progression of disease maybe can be considered shorter than the 2 years of 
treatment in Bell et al. (2012). In Zidan et al. (2010) the criteria for termination of previous anti-
cancer treatment was determined to be at least 1 month before initiation of letrozole treatment and 
the median time for the termination was 12 months. In Bell et al. (2012) no such termination time is 
set (or at least described) and thus the effects of prior treatment can possibly influence the measured 
values at both baseline and after 3 months of AI treatment. In the exclusion from lipid analysis by 
Bell et al. (2012) the sum of the excluded participants (n=254) subtracted from all the enrolled par-
ticipants (n=503-254) gives another number (n=249) that the number of the included participants 
(n=246). This is not mentioned in the study but perhaps it is due to deaths during the trial. Further-
more some of the exclusion criteria are made to adjust for confounders. Because of Bell et al. 
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(2012) only measuring values at baseline and after 3 months of AI treatment it is impossible to say, 
if the changed lipid values would have returned to baseline values after 6 or 12 months or treatment. 
Table x.x is a comparison of the measured values in each of the studies after 3 months of treatment 
with letrozole (modified from Zidan et al., 2010; Bell et al., 2012). 
Alteration/measured Bell et al., 2012 Zidan et al., 2010 
TC Significantly increased Insignificantly increased 
HDL-C Insignificantly decreased Insignificantly increased 
LDL-C Significantly increased Significantly increased 
LDL/HDL ratio Significantly increased Not registered 
TG Insignificantly increased Baseline-like value 
Table shows the results after 3, 6, and 12 months of treatment with letrozole (modified from Zidan 
et al., 2010). 
 
Alteration/measured After 3 months After 6 months After 12 months 
TC Insignificantly in-
crease 
Returned to baseline 
value 
Returned to baseline 
value 
HDL-C Insignificantly in-
creased 
Returned to baseline-
like value 
Returned to baseline-
like value 
LDL-C Significantly incre-
ased 
Significantly increased Returned to baseline 
value 
TG Baseline-like value Insignificantly increa-
sed 
Insignificantly increa-
sed 
Estradiol Significantly decre-
ased 
Significantly decreased Significantly decreased 
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In the substudy conducted by Bell et al. (2012) the participants besides AI treatment also used lipid-
altering medication. The population was generally older and had an increased BMI but was other-
wise similar. The results of the substudy showed that all the measured values significantly were 
lower at baseline compared to the patients only treated with AI except for triglycerides. Overall AI 
therapy induced a significant decrease in TC and HDL-C. Also these patients were stratified in re-
gard to prior tamoxifen use (Bell et al., 2012). 
Adverse effects on lipids are undesirable due to cholesterol and triglycerides indicating long-term 
cardiovascular disease risk (Bell et al., 2012). HDL-C was not significantly changed in letrozole 
patients but for women both taking letrozole and lipid-lowering medication a significant reduction 
was observed. The study by Bell et al. (2012) is the first comparison of steroidal and nonsteroidal 
AI in postmenopausal women with breast cancer and the first to independently analyze patients 
treated with both an AI and lipid-lowering medication. 
Prior use of tamoxifen was an independent predictor of increased LDL both in the entire cohort and 
for letrozole users which makes sense because tamoxifen reduces LDL-C. Prior tamoxifen use in 
the exemestane group did not increase LDL-C as pronounced as in letrozole, especially in the lipid-
lowering group which means that letrozole possibly increases LDL. 
Conclusively, long-term observations of effects of AI are important (Bell et al., 2012). 
In the study conducted by Zidan et al. (2010) it was concluded that the letrozole does not affect the 
lipid profiles or triglycerides of women with breast cancer but suppresses estradiol to a high degree. 
Whereas the conclusion of the other study (Bell et al., 2012) was that significant and adverse 
changes of the lipid profiles of breast cancer patients was observed but it was not possible to deter-
mine whether the observations were due to tamoxifen washout or AI treatment. 
Other studies have proposed that nonsteroidal and steroidal AIs are equally effective and safe due to 
indirect comparisons but yet others found different results in regard to lipid profiles for exemestane 
and letrozole (Bell et al., 2012). This is suggested by Bell et al. (2012) to possible be due to differ-
ences in study design and genetic and/or population differences. 
Statins and breast cancer risk 
Intro: The articles this report used for its analysis of the association between statin use and cancer-
related mortality and breast cancer mortality were selected on the basis of the meta-analysis by 
Zhong et al. (2015) that used 41 articles; “thirty-nine cohort studies and two case-control stud-
ies”(Zhong et al., 2015). 
 
 
Page 38 af 53 
 
The articles used for this analysis were based on criteria; the size of the study population, ethnicity, 
statins’ impact on cancer mortality and breast cancer mortality, and that they fulfilled the search 
criteria.  
Zhong et al. (2015) examined the therapeutic value of statins and their association with survival in 
cancer patients for both cancer-specific mortality and all-cause mortality in relation to pre-diagnosis 
and post-diagnosis. The study (Zhong et al., 2015) involved 990,649 participants. The articles used 
for the meta-analysis were only included if they met the inclusion criteria; 
 
a)      The exposure of interest was statin use assessed before or after diagnosis 
b)      The study design was case control or cohort 
c)      The outcomes of interest were all-cause mortality or cancer-specific mortality 
d)     The follow-up period was longer than 1 year 
e)      Risk estimates of mortality and 95% confidence intervals (CIs) were reported (or infor-
mation to calculate them (Zhong et al., 2015). 
The results from the 41 articles were all gathered in a table (appendix 4) after “name of the author, 
year, country, follow-up period, study design, patient characteristics, statin use, cancer-specific 
mortality, all-cause mortality, and covariate adjustment” (Zhong et al., 2015). One of the largest 
cancer groups in (Zhong et al., 2015) was breast cancer, which showed a benefit from statin use. It 
was observed that post-diagnosis statin use, reduced the “risk of death from cancer in breast pa-
tients”(Zhong et al., 2015). Statin use prior to diagnosis reduced the risk of any cause of death in 
breast cancer patients and a decrease in death from cancer was also observed (Zhong et al., 2015).  
 
Conclusion regarding statins and breast cancer risk 
The average effect of statin use compared with non-users had a beneficial effect (Zhong et al., 
2015) for overall survival and cancer-specific survival (Zhong et al., 2015) in both pre-diagnosis 
and post-diagnosis (figure A and B). 
 
Table ST.1 The association with post-diagnosis statin use with mortality (Zhong et al., 2015). 
Group Pre-diagnosis statin use in relation to all-
cause mortality 
Post-diagnosis statin use in relation to 
all-cause mortality 
Stratified by Reduced risk of death from any cause was Statin use was associated with decreased 
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cancer type found in both breast and colorectal cancer 
patients 
risk of death from prostate and ovarian 
cancer 
Subgroup by 
gender 
Significant benefit for overall survival in 
both male and females 
Significant benefits for overall survival 
in both male and females 
 
Table ST.2 The association with pre-diagnosis statin use and mortality (Zhong et al., 2015). 
Group Pre-diagnosis statin use in relation to 
cancer-specific mortality 
Post-diagnosis statin use in relation to 
cancer-specific mortality 
Stratified by 
cancer type 
Decreased risk of death from cancer in 
breast, colorectal and prostate cancer 
patients 
Decreased risk of death from cancer 
found in breast and prostate cancer 
patients 
Subgroup by 
gender 
Significant beneficial for survival in both 
male and females 
No association in women, but in males a 
decrease in mortality was observed 
 
The first article selected from the meta-analysis Zhong et al., (2015) conducted by (Nielsen, 
Nordestgaard, & Bojesen, 2012)), that examined the use of statins and cancer mortality in patients 
from the Danish population who had received a diagnosis between 1995 and 2007 (Nielsen et al., 
2012) and followed them until December 31, 2009. The group consisted of 295,925 patients out of 
which 18,721 had used statins regularly before diagnosis and 277,204 reported to never had used 
statins (Nielsen et al., 2012). The cancer patients included were age 40 or older, those under age 40 
were excluded. Statin users that have statin prescriptions filled 2 years before diagnosis and down to 
at least 6 months before diagnosis were defined as regular users (Nielsen et al., 2012). 
Statin use was only recorded before the date of cancer diagnosis from patients prescription and was 
used to indicate statin use before and after cancer diagnosis. Information about diagnosis of cardio-
vascular diseases and diabetes was gathered, but did not have any effect on the outcome of the 
study. Information about covariates such as race, ethnic descent, levels of education, size of residen-
tial area was gathered for all patients (Nielsen et al., 2012). 
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Results regarding statins and breast cancer 
During the follow-up  which ended december 31, 2009, 195,564 patients died, 162,067 deaths were 
cancer related, 14,489 deaths was caused by cardiovascular diseases and 19,038 deaths were due to 
other causes (Nielsen et al., 2012). There was a difference between statin-users and non-users. Both 
any cause of death and deaths caused by cancer were lower among statin-users (figure A). thatmay 
be caused by statins cholesterol-independent effects. Because of the cardiovascular mortality among 
statin users the curve converge after 5 years (Nielsen et al., 2012). 
 
Figure A (Nielsen et al., 2012). 
 
The second article that fulfilled the search criteria was a study conducted by Desai et al. (2015) used 
the Women’s Health Initiative to collect data and investigate prior statin use and breast cancer stage 
at diagnosis and mortality. The results showed that breast cancer mortality was slightly lower in 
statin users compared with non-users and that statins were associated with lower breast cancer stage 
at diagnosis. The study was composed of an observational study (n= 93,676) and clinical trials (n = 
68,132). Desai et al. (2015)  excluded women “who did not report a mammogram within 5 years of 
study entry, women with no health insurance, no reported medical care provider, prior history of 
breast cancer, no information on follow-up, missing information on stage in incident breast cancer, 
and missing information on baseline statin use” (Desai et al., 2015). This resulted in a study popula-
tion including 128,675 postmenopausal women aged 50 – 79 years (Desai et al., 2015). At the be-
ginning of the study, there were diagnosed 7,883 newly cases of in situ, local, regional and distant 
stage breast cancer (Desai et al., 2015). The cases were stratified into early (in situ and local) versus 
late (regional and distant) stage breast cancer (Desai et al., 2015). The study was terminated in 
2010. “Information on statin intake was collected at years 1, 3, 6 and 9 in the clinical trials, and year 
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3 in the observational study” (Desai et al., 2015). The participants were listed in table 1 (appendix 
x) that included socio-demographic and medical history, variables that could have an impact on the 
outcome of the study (Desai et al., 2015). 
Results regarding statins and breast cancer 
Lipophilic statins were associated with a reduction in diagnosis of late-stage breast cancer com-
pared to non-users and also  a significantly lower risk among women with late-stage ER-positive 
breast cancer in the time-dependent analysis was found (Desai et al., 2015). The mortality was 
slightly lower in statin users compared with non-users in the time dependent analysis but not in the 
multivariable model (Desai et al., 2015). The result fit to the theory that statins may act as chemo-
therapeutic agents through cholesterol-independent pathway. In the late-stage breast cancer models, 
women were censored if they had early-stage breast or died during follow-up. Censoring the women 
who died under follow-up shows a misleading association between statin use and late-stage breast 
cancer. Censoring women that died under the follow-up, they are not accounted for in the effect of 
statins and their association with late-stage breast cancer, which shows a wrong result of statins 
chemotherapeutic effects. 
 
Model Multivariable model Multivariable time-dependent analysis 
Late-stage breast 
cancer (LSBC) 
No significant association between 
statin use at baseline and LSBC 
Modest but non-significant reduction 
in LSBC 
LSBC, statin use, and 
ER+ 
A nonsignificant trend toward a lower 
risk of LSBC ER+ among statin users 
Significantly lower risk of LSBC and 
ER+ 
Statin lipophilicity Statin lipophilicity did not have a 
significant development of LSBC 
Significantly lower hazard of LSBC 
among women that used lipophilic 
statins 
BREAST CANCER 
mortality 
No significant relationship between 
statin use and BREAST CANCER-
specific mortality 
Statin use associated with decreased 
risk of BREAST CANCER- mortality 
over time 
BREAST CANCER, No information given No significant association between 
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statin use, and ER+ statin use and BREAST CANCER 
mortality and ER+ 
Statin lipophilicity No significant relationship between 
type of statin and BREAST CANCER-
mortality 
No information given 
 
As the table shows there was a non-significant association between statin use, late-stage breast can-
cer and cancer-specific mortality in the multivariable models also when stratified by ER status. In 
the multivariable time-dependent model, there was a reduction in LSBC with statin use but non-
significant. There was a significantly lower risk of LSBC when stratified by ER status. Statin use 
was also associated with decreased risk of BC mortality in time-dependent analysis but no associa-
tion was seen when stratified by ER status. 
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Discussion 
The discussion will be based on the meta-analyses and the associated studies used in the analysis. 
Most of the analysis and studies focus on the risk and the mortality of cancer and breast cancer. 
This report tries to estimate whether statins reduce recurrence or not. Thus it will be assumed that 
the risk of breast cancer can be compared to recurrence in the following discussion. 
BMI, estrogen, and breast cancer risk 
In this part of the discussion it is mainly the first theory mentioned in chapter 1 about the associa-
tion between estrogen and breast cancer: The binding between estrogen and ER enhances cell pro-
liferation of mammary cells, and increase in cell division and DNA synthesis elevates the risk for 
replication errors that may result in mutations (Deroo & Korach, 2006) that will be focused on (see 
chapter 1.1). The reason for this is that no studies were found to assess the second thesis point muta-
tions 
In the meta-analysis “Body Mass Index, Serum Sex Hormones, and Breast 
Cancer Risk in Postmenopausal Women” (Key et al., 2003) an association between an increase in 
BMI and increased serum estradiol is not surprising. This is however not entirely surprising. As 
obesity is established as a risk factor for breast cancer in postmenopausal women (Cleary & 
Grossmann, 2009) and the main estrogen source for postmenopausal women is production in the 
adipose tissue (Yaghjyan & Colditz, 2011), it can be assumed that an increase in BMI also would 
cause an increase in estrogen producing cells and thereby an increase in the serum estrogen. The 
studies involved in the meta-analysis by Key et al (2003) all contributed to the hypothesis that high 
serum sex hormone levels and more specific estrogens preceded the development of breast cancer. 
This association between serum estrogens, BMI and the risk of developing breast cancer, might be 
applicable to the the risk factors of recurrence. Especially the association between risk of recurrence 
of breast cancer and high estrogen levels is supported by the fact that patients are given letrozole as 
a prevention for recurrence. The estrogen levels are reduced and so is the risk of recurrence. 
(Fedele et al., 2014) contribute to this possible association between high estrogen levels and breast 
cancer with the association they found that patients with increased BMI after treatment have in-
creased risk of recurrence. The risk of recurrence was a significantly increased if the patient gained 
2 kg/m
2
 or more after treatment. This means that a postmenopausal woman with a normal BMI at 
23kg/m
2
 who were 1,65m tall would have an increased risk of recurrence if she gained 5.45 kg. An 
argument against this association with increase in BMI for increase in risk of breast cancer, is that 
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serum levels of hormones measured in the blood is not a complete representative for the estrogen 
production in the adipose tissue, but merely a representative of travelling estrogen in the blood. But 
as the proliferation of  cells is stimulated by the ER which are activated by estrogen, it is not really 
important where the estrogen in the blood comes from, if the focus is only on the association of risk 
for  related to estrogen. But as mentioned before, the adipose tissue is the main location for estrogen 
production in postmenopausal women, thus making the association with increased BMI possible. 
The connection between breast cancer risk and BMI could also be a connection to hypercholesterol-
emia as obesity and hypercholesterolemia is often connected and BMI is recognized as a risk factor 
for breast cancer. If BMI increases with hypercholesterolemia, then the connection that is shown in 
Zohng which is that statins reduce the risk of breast cancer could be possible. The argument for this 
is that if hypercholesterolemia contributes to the increase in BMI, then lowering of cholesterol will 
make it easier to decrease BMI and through that maybe the amount of adipose tissue and thereby 
the estrogen production and the risk for recurrence. 
MS, letrozole, and breast cancer risk 
It is known that women with breast cancer have higher estrogen levels than women without breast 
cancer (Key et al., 2003). Also women with increased BMI have higher estrogen levels due to in-
creased adipose tissue and aromatization. Furthermore postmenopausal women’s estrogen produc-
tion in the ovaries is highly reduced and most of the production happens in the adipose tissue (Ya-
ghjan & Colditz, 2011). Thus postmenopausal women have increased risk of ER+ breast cancer, 
especially postmenopausal women with increased BMI. In the study concerning BMI and breast 
cancer risk (Key et al., 2003) it was found that the higher breast cancer risk related to higher BMI is 
due to an increased estrogen production. 
Women with metabolic disease generally have increased BMI, decreased HDL-C, and increased 
levels of TG. In the study concerning MS (Esposito et al., 2013) both increased BMI and decreased 
HDL-C were associated with increased breast cancer risk but increased TG showed no association 
(Esposito et al., 2013). It could not be identified whether the individual components combined or 
the full syndrome, were associated with a greater risk of postmenopausal breast cancer or not (Es-
posito et al., 2013). Furthermore it is not possible to determine if it is all of the components or only 
some or if it is the association of the components of the syndrome that induces the increased risk of 
postmenopausal breast cancer (Esposito et al., 2013). 
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Letrozole is suspected to induce hypercholesterolemia but suppresses estrogen and thus reduces 
breast cancer recurrence risk to a very high degree. It is therefore important to investigate letro-
zole’s influence on lipid profiles to determine its possible adverse effects compared to its desired 
and effective suppression of estrogen. In one (Bell et al., 2012) of the two studies (Zidan et al., 
2010; Bell et al., 2012) concerning letrozole processed in the analysis of this report, an adverse ef-
fect on the lipid profile of women with breast cancer after 3 months of letrozole treatment was ob-
served. But it must be taken into consideration that prior to letrozole treatment, 43 % of the letro-
zole group had been treated with tamoxifen so the alteration of the lipid profile could partly be due 
to tamoxifen washout because tamoxifen has a reducing effect on the lipids. The possible effect of 
tamoxifen washout depends on the termination of tamoxifen treatment and tamoxifen’s “washout-
time”. The study does not mention how long before letrozole treatment the prior treatment was ter-
minated. Additionally, the altered lipid profiles could possibly change further after the 3 months 
measurement and this is not accounted for in the study. Conclusively, the study demonstrated ad-
verse short-term effects of treatment with letrozole that could possibly be due to tamoxifen wash-
out. In regard to the results accomplished in the study (Bell et al., 2012) letrozole treatment could 
possibly induce hypercholesterolemia due to the significantly increased TC, LDL-C, and LDL/HDL 
ratio after the 3 months treatment. Furthermore HDL-C was insignificantly decreased which also 
can be a component in inducing hypercholesterolemia. 
The other study (Zidan et al., 2010) concerning letrozole also showed an adverse effect of letrozole 
after 3 months treatment but the adverse changes in the lipid profiles were all returned to baseline 
after 12 months of treatment. Only TG was insignificantly increased after 12 months treatment but 
this do not affect the risk of breast cancer due to the meta-analysis regarding MS (Esposito et al., 
2013) which showed that high levels of TG were not associated with increased breast cancer risk. 
However increased levels of TG may be associated with hypercholesterolemia. 
The differences between the results after three months treatment of letrozole in the two studies (Zi-
dan et al., 2010; Bell et al., 2012) may be due to several factors. Some of the values are different 
according to increase or decrease, whereas the others differ by the significance in alteration or no 
alteration at all. First of all, both the TC and the LDL-C values are increased. In both studies LDL-
C is increased significantly. This could either mean that letrozole influences the LDL-C directly or 
that the potential washout of tamoxifen does. The TC value is significantly increased and the TG 
value is insignificantly increased in the study by Bell et al. (2012) whereas the TC value is insignif-
icantly increased and the TG value is baseline-like (Zidan et al., 2010). This shows that all these 
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three values (TC, LDL-C, and TG) from the study conducted by Bell et al. (2012) are more distinc-
tively increased than those in the other study. However it should be noted that these three values 
(Bell et al., 2012) all were lower at baseline than those in the study by Zidan et al. (2010). The 
HDL-C on the other hand was respectively decreased (Bell et al. 2012) and increased (Zidan et al., 
2010) but insignificantly for both studies. None of the studies included patients using lipid-altering 
medication, the mean age did not differ much. It was 57 years for patients receiving letrozole (Bell 
et al., 2012) and 56 years (Zidan et al., 2010). But the number of participants varied greatly by 50 
compared to 246. Furthermore the ethnicity varied between the two studies and among the partici-
pants within the study. Additionally the termination of prior anticancer treatment was not accounted 
for in one of the studies (Bell et al., 2012) while it should be at least 1 month before initiation of 
letrozole treatment in the other (Zidan et al., 2010). This can possibly influence the differences in 
the results. Also the type of prior treatment may affect the results together with lack of adjustment 
for this. Another condition to take into consideration is that Bell et al. (2012) investigated both ex-
emestane and letrozole and thus the overall conclusion is marked by this, e.g. due to exemestane’s 
significant decrease of HDL-C which could be caused by exemestane producing an androgenic me-
tabolite that binds to the androgen receptor and androgens having an adverse effect on HDL-C. 
In the study by Bell et al. (2012) a substudy was conducted. Approximately 24 % of the enrolled 
participants in the primary study used lipid-altering medication. The substudy consisted of partici-
pants (n=95) receiving either letrozole (n=54) or exemestane (n=41) combined with lipid-altering 
medication. 86 of the 95 participants used statins. 
The results showed that the group using lipid-altering medication was not protected against the ad-
verse effect of letrozole on the lipid profile (Bell et al., 2012) even though it was only the signifi-
cant decrease in HDL-C and thus an increase in the LDL/HDL ratio which was adverse overall. 
This is not necessarily unexpected because statins and letrozole (possibly) affect cholesterol in two 
different ways. But it has not been investigated whether these two different effects are related – 
directly or indirectly – through pathways or reversible mechanisms. The alteration of the lipid pro-
files may be especially adverse in the substudy group to whom an alteration is undesirable due to 
their increased risk of cardiovascular disease besides the general increased risk of breast cancer re-
currence. This indicates that in regard to letrozole’s effect on altered lipid profiles which is related 
to increased breast cancer risk and thus recurrence, patients using lipid-lowering medication 
(statins) do not have a decreased risk of recurrence of breast cancer and furthermore they are at risk 
of getting cardiovascular disease. 
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In regard to this report the alteration in lipid profiles are interesting because patients with hypercho-
lesterolemia are prescribed statins and statins may have a beneficial effect on breast cancer. Thus, if 
letrozole alters the lipid profiles negatively that could maybe lead to hypercholesterolemia which 
when diagnosed can be treated with statins. 
Statins and breast cancer risk 
Several studies have examined the association between statins and cancer, but show inconsistent 
results.  It is assumed that statins have anti-cancer effects by inhibiting HMG-CoA reductase and 
inhibit the downstream products of the MVA pathway that are important for proper cellular func-
tions (see chaper 6.1). 
Zhong et al., (2015) observed that statin use, both post-diagnosis and pre-diagnosis, was beneficial 
for overall and cancer-specific survival. This did not differ from the results in Desai et al., (2015) 
and Nielsen et al., (2012), which observed beneficial effects of statin use and cancer-related mor-
tality compared to statin non-users. Desai et al., (2015) observed that statins were associated with 
lower breast cancer-stage at diagnosis and a reduced cancer-related mortality was observed in can-
cer patients (Nielsen et al., 2012). The association between statins and cancer showed beneficial 
effects compared to non-users in all three studies (Desai et al., 2015; Nilsson et al., 2001; Zhong et 
al., 2015). There were a lot of similarities in the methods in studies which may explain some of the 
similarities. The results from Desai et al., (2015) differed a bit from Nielsen et al., (2012) 
and  Zhong et al., (2015) because the beneficial effects of statins were found in the multivariable 
time-dependent analysis and not it the multivariable model. It may be assumed on the basis of the 
results in (Desai et al., 2015) that statins’ beneficial effects only works in a time-frame. May due to 
the explanation that the patients became resistant to statins over time. Desai et al., (2015) & Nielsen 
et al., (2012) are some of the studies with a greater population included in the meta-analysis Zhong 
et al., (2015) and may therefore have a more reliable result compared to a smaller study as (Lip-
worth et al., 2013) used in the meta-analysis (Zhong et al., 2015). This study observed no associa-
tion between statin use and cancer-mortality (Lipworth et al., 2013). The explanation for a different 
result may be due to the ethnicity of the population, that contained black and white people in the 
Southeastern United States. Little is known about statin use in black people, they may not have the 
same beneficial effect from statins as the study population in Desai et al., (2015) and  Nielsen et al., 
(2012), which involved patients from Denmark (WHI and Danish Cancer registry). The majority of 
the study population in Desai et al., (2015) and Lipworth et al., (2013) used lipophilic statins and 
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the same is applied in (Nielsen et al., 2012) although it is not mention, it is assumed out from the 
data from Roskilde hospital that showed that the majority of the breast cancer patients were pre-
scribed lipophilic statins. The use of lipophilic statins may be the reason for that the cancer-
mortality in (Lipworth et al., 2013) did not decrease. If the majority of the patients in (Lipworth et 
al., 2013) had been prescribed hydrophilic statins instead, the decrease in cancer-mortality may had 
been decreased. Statins anticancer and anti-invasive effetcts may be caused by cholesterol inde-
pendent effects such as the inhibition of the isoprenoids FPP and GGPP (see chap 6.1) are involved 
in posttranslational modification of many proteins, that are important for cellular functions such as 
cell proliferation (Desai et al., 2015), gene expression and more (Nielsen et al., 2012). Disruption of 
these proteins malignant cells results in inhibition of cancer growth and metastasis (Nielsen et al., 
2012). 
 
To investigate the connection between statins and reduction in recurrence risk further might be ben-
eficial to make an intervention study where some postmenopausal women without hypercholester-
olemia is given statins and then compared to a control group with the same criteria. The group have 
investigated the statin use in postmenopausal women in Region Sjaelland (appendix 6) which 
showed that approximately 30% of the population were given statins. It is possible that if, as a part 
of the intervention study, all these woman were screened for hypercholesterolemia, even more 
woman would prove to benefit from the statin use. This would leave a small population, that then  
had to be split in two to have a control group and  a group who were given statins. The group given 
statins would be too small to be more than hypothesis generating.  
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Conclusion 
 
The studies showed a lot of different results which perhaps was due to different populations and 
genetic variation.  BMI was associated with increased risk of breast cancer due to increased estro-
gen levels. Metabolic disease showed that some of the components were associated with increased 
breast cancer risk but these components were not necessarily affected by letrozole treatment, which 
was suspected. The results of the letrozole treatment differed both due to duration-time, population, 
and prior treatment, especially tamoxifen. Thus it could not be concluded whether letrozole affected 
the lipid profiles of postmenopausal women with breast cancer negatively. In the studies concerning 
statin the results also differed. This was due to time-dependency, ethnicities, and type of statin. Fur-
thermore our own data showed that approximately 30 % of the postmenopausal breast cancer pa-
tients were treated with statins. Thus it was not possible for us to answer the problem of interest. 
But a way to investigate this could be done through an intervention study to investigate statins in-
fluence on postmenopausal women with breast cancer. However this cannot be done because 30 % 
of the patients already receive statins and in an investigated population more of the patients would 
probably have hypercholesterolemia and would have to be censored. After all, statins do seem to 
have a positive association with breast cancer risk and thus breast cancer recurrence but this needs 
further investigation. 
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